Pembrolizumab (MK-3475) and Bacillus Calmette-Guérin (BCG) as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer (NMIBC) and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma (NMI-UTUC)]
Clinical trial NCT03504163 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03504163
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-06-27
- Primary completion
- 2027-04-01
- Enrollment
- 45
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.